A Phase 3 interventional study of Zanubrutinib and Ibrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by BeiGene. Completed at 115 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-30.
Sponsored by BeiGene · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing zanubrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 11 open to participants now, 17 under way, 3 of them phase 3. zanubrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 22 studies testing zanubrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one has the largest enrollment, is the only one that started in 2018, is one of 4 in phase 3, and was the 3rd registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →11 of the 22 studies testing zanubrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:
Kerry Rogers · Sites in United States
Ages 18+
BeOne Medicines · Sites in United States, Australia, Brazil and 14 more countries
Ages 18+
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–80
City of Hope Medical Center · Sites in United States
Ages 18+
PETHEMA Foundation · Sites in Spain
Ages 18+
By country, each count listing its studies:
zanubrutinib: first FDA approval 2019 (BRUKINSA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 16 · Phase 3 4
First in 2017; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 652 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 71 across the 22 interventional studies. Of the 4 that completed or were terminated, 2 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 22 have an industry lead sponsor. The 10 most frequent:
This study is registered under BeiGene, one of the names counted as BeOne Medicines. Under that name alone:
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
18 studies in Leukemia, Lymphocytic, Chronic, B-Cell by BeOne Medicines: 7 open now, 12 under way, 7 of them phase 3. Of 6 finished, 3 (50%) have results posted.
Among the 18 studies in Leukemia, Lymphocytic, Chronic, B-Cell by BeOne Medicines, this one is the 2nd largest by enrollment, is the only one that started in 2018, is one of 8 in phase 3, and was the 3rd registered.
BeOne Medicines’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 2017.
6 of the studies testing zanubrutinib in Leukemia, Lymphocytic, Chronic, B-Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05873712Aseel AlsouqiZanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome | 2026-12-31 |
| NCT03824483Memorial Sloan Kettering Cancer CenterStudy of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) | 2027-02 |
| NCT07674810M.D. Anderson Cancer CenterA Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia | 2027-04-30 |
| NCT04458610M.D. Anderson Cancer CenterZanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | 2027-05-26 |
| NCT07003464The First Hospital of Jilin UniversityPhase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study | 2027-06-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 22 studies testing zanubrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Among BeOne Medicines’s 18 in Leukemia, Lymphocytic, Chronic, B-Cell:
This tab as a report to print or save as PDF → With an account.
This study is designed to compare the overall response rate of zanubrutinib versus ibrutinib in participants with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
This is a global, Phase 3, randomized study of zanubrutinib versus ibrutinib in 652 participants with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
The primary efficacy endpoint is overall response rate determined by investigator assessment. Participants were randomized in a 1:1 manner to either zanubrutinib or ibrutinib. Treatment with zanubrutinib and ibrutinib was open label.
Key Inclusion Criteria
Key Exclusion Criteria
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 160 mg zanubrutinib orally twice daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.
Drug: Zanubrutinib
Participants received Ibrutinib 420 mg orally once daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.
Drug: Ibrutinib
160 mg orally twice daily
Also known as: BGB-3111, Brukinsa
Ibrutinib 420 mg orally once daily
Also known as: Imbruvica
Overall Response Rate (ORR) Assessed by the Investigator
ORR is defined as the percentage of participants with a complete response (CR) / complete response with incomplete bone marrow recovery (CRi), nodular partial response (nPR) or partial response (PR) per investigator assessment. Disease response was assessed in accordance with the 2008 criteria of the International Workshop on CLL (IWCLL), with modification for treatment-related lymphocytosis in participants with CLL and in accordance with the Lugano classification in participants with SLL.
Time frame: From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).
ORR Assessed by the Independent Review Committee (IRC)
ORR is defined as the percentage of participants with a complete response (CR) / complete response with incomplete bone marrow recovery (CRi), nodular partial response (nPR) or partial response (PR) assessed by a blinded independent review committee. Overall response was assessed by the IRC for the purpose of regulatory filing with the Food and Drug Administration (FDA). Disease response was assessed in accordance with the 2008 criteria of the International Workshop on CLL (IWCLL), with modification for treatment-related lymphocytosis in participants with CLL and in accordance with the Lugano classification in participants with SLL.
Time frame: From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).
Progression-free Survival (PFS) Assessed by the Investigator
PFS is defined as the time from randomization to the date of first documentation of disease progression or death, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.
Time frame: From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).
Progression-free Survival Assessed by the Independent Review Committee
PFS is defined as the time from randomization to the date of first documentation of disease progression or death, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.
Time frame: From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).
Percentage of Participants With Atrial Fibrillation or Atrial Flutter
Participants were considered as having an atrial fibrillation/flutter event if they had a treatment-emergent AE of either "atrial fibrillation" or "atrial flutter".
Time frame: From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).
Duration of Response Assessed by the Independent Review Committee
DOR is defined as the time from the date that response criteria were first met to the date that disease progression was objectively documented or death, whichever occurred first, determined by independent central review. Median DOR was estimated using the Kaplan-Meier method.
Time frame: From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).
Duration of Response (DOR) Assessed by the Investigator
DOR is defined as the time from the date that response criteria were first met to the date that disease progression was objectively documented or death, whichever occurred first, determined by investigator assessment. Median DOR was estimated using the Kaplan-Meier method.
Time frame: From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).
Time to Treatment Failure
Time to treatment failure is defined as the time from randomization to discontinuation of study drug due to any reason. Median time to treatment failure was estimated by the Kaplan-Meier method.
Time frame: From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).
Rate of Partial Response With Lymphocytosis (PR-L) or Higher Assessed by the Independent Review Committee
The rate of partial response with lymphocytosis or better is defined as the percentage of participants who achieved a complete response or a complete response with incomplete bone marrow recovery (CR/CRi), nodular partial response, partial response, or partial response with lymphocytosis assessed by the blinded IRC. Disease response was assessed per iwCLL 2008 criteria, with modification for treatment-related lymphocytosis for participants with CLL and per Lugano classification for participants with SLL.
Time frame: From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).
Rate of Partial Response With Lymphocytosis (PR-L) or Higher Assessed by the Investigator
The rate of partial response with lymphocytosis or better is defined as the percentage of participants who achieved a complete response or complete response with incomplete bone marrow recovery (CR/CRi), nodular partial response, partial response, or partial response with lymphocytosis as assessed by the investigator. Disease response was assessed according to the iwCLL 2008 criteria, with modification for treatment-related lymphocytosis for participants with CLL and in accordance with Lugano classification for participants with SLL. Partial response with lymphocytosis: blood lymphocytes decreased \< 50% or increased from baseline, and otherwise meeting criteria for PR.
Time frame: From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).
Overall Survival (OS)
Overall survival is defined as the time from randomization to the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method.
Time frame: From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (GHS)/Quality of Life (QOL), Physical Functioning and Role Functioning Scores
The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. Higher scores in GHS and functional scales indicate better quality of life.
Time frame: Baseline and Weeks 24 and 48
Change From Baseline in EORTC QLQ-C30 Symptom Scales of Fatigue, Nausea and Vomiting, Pain, and Diarrhoea
The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. Lower scores in symptom scales indicate better quality of life.
Time frame: Baseline and Weeks 24 and 48
Change From Baseline in European Quality of Life 5-dimensions 5-levels Health Questionnaire (EQ-5D-5L) Visual Analog Scale (VAS)
The EQ-5D-5L VAS measures a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' A higher score indicates better health outcomes.
Time frame: Baseline and Weeks 24 and 48
Number of Participants With Treatment-emergent Adverse Events (TEAE)
An adverse event is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to study drug or not. A serious adverse event (SAE) is any untoward medical occurrence that, at any dose: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization * Resulted in disability/incapacity * Resulted in a congenital anomaly/birth defect * Was considered a significant medical AE by the investigator based on medical judgment
Time frame: From first dose of study drug up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm.
This study was conducted at 113 study centers in 15 countries (Australia, Belgium, China, the Czech Republic, France, Germany, Italy, the Netherlands, New Zealand, Poland, Spain, Sweden, Turkey, the United Kingdom, and the United States).
| Milestone | Zanubrutinib | Ibrutinib |
|---|---|---|
| Started | 327 | 325 |
| Received study drug | 324 | 324 |
| Completed | 0 | 0 |
| Not completed | 327 | 325 |
| Withdrew: Sponsor ended study | 225 | 200 |
| Withdrew: Death | 69 | 83 |
| Withdrew: Withdrawal by subject | 21 | 27 |
| Withdrew: Physician decision | 1 | 12 |
| Withdrew: Lost to follow-up | 6 | 2 |
| Withdrew: Miscellaneous | 5 | 1 |
ORR is defined as the percentage of participants with a complete response (CR) / complete response with incomplete bone marrow recovery (CRi), nodular partial response (nPR) or partial response (PR) per investigator assessment. Disease response was assessed in accordance with the 2008 criteria of the International Workshop on CLL (IWCLL), with modification for treatment-related lymphocytosis in participants with CLL and in accordance with the Lugano classification in participants with SLL.
| percentage of participants | Zanubrutinib | Ibrutinib |
|---|---|---|
| Overall Response Rate (ORR) Assessed by the Investigator | 83.5 (79.0 to 87.3) | 74.2 (69.0 to 78.8) |
ORR is defined as the percentage of participants with a complete response (CR) / complete response with incomplete bone marrow recovery (CRi), nodular partial response (nPR) or partial response (PR) assessed by a blinded independent review committee. Overall response was assessed by the IRC for the purpose of regulatory filing with the Food and Drug Administration (FDA). Disease response was assessed in accordance with the 2008 criteria of the International Workshop on CLL (IWCLL), with modification for treatment-related lymphocytosis in participants with CLL and in accordance with the Lugano classification in participants with SLL.
| percentage of participants | Zanubrutinib | Ibrutinib |
|---|---|---|
| ORR Assessed by the Independent Review Committee (IRC) | 86.2 (82.0 to 89.8) | 75.7 (70.7 to 80.3) |
PFS is defined as the time from randomization to the date of first documentation of disease progression or death, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.
| months | Zanubrutinib | Ibrutinib |
|---|---|---|
| Progression-free Survival (PFS) Assessed by the Investigator | NA (34.3 to NA) | 34.2 (33.3 to NA) |
PFS is defined as the time from randomization to the date of first documentation of disease progression or death, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.
| months | Zanubrutinib | Ibrutinib |
|---|---|---|
| Progression-free Survival Assessed by the Independent Review Committee | NA (34.3 to NA) | 35.0 (33.2 to 44.3) |
Participants were considered as having an atrial fibrillation/flutter event if they had a treatment-emergent AE of either "atrial fibrillation" or "atrial flutter".
| percentage of participants | Zanubrutinib | Ibrutinib |
|---|---|---|
| Percentage of Participants With Atrial Fibrillation or Atrial Flutter | 5.2 (3.1 to 8.3) | 13.3 (9.8 to 17.5) |
DOR is defined as the time from the date that response criteria were first met to the date that disease progression was objectively documented or death, whichever occurred first, determined by independent central review. Median DOR was estimated using the Kaplan-Meier method.
| months | Zanubrutinib | Ibrutinib |
|---|---|---|
| Duration of Response Assessed by the Independent Review Committee | NA (31.3 to NA) | 33.9 (32.2 to 41.4) |
DOR is defined as the time from the date that response criteria were first met to the date that disease progression was objectively documented or death, whichever occurred first, determined by investigator assessment. Median DOR was estimated using the Kaplan-Meier method.
| months | Zanubrutinib | Ibrutinib |
|---|---|---|
| Duration of Response (DOR) Assessed by the Investigator | NA (31.3 to NA) | 33.9 (33.9 to NA) |
Time to treatment failure is defined as the time from randomization to discontinuation of study drug due to any reason. Median time to treatment failure was estimated by the Kaplan-Meier method.
| months | Zanubrutinib | Ibrutinib |
|---|---|---|
| Time to Treatment Failure | NA (NA to NA) | NA (34.4 to NA) |
The rate of partial response with lymphocytosis or better is defined as the percentage of participants who achieved a complete response or a complete response with incomplete bone marrow recovery (CR/CRi), nodular partial response, partial response, or partial response with lymphocytosis assessed by the blinded IRC. Disease response was assessed per iwCLL 2008 criteria, with modification for treatment-related lymphocytosis for participants with CLL and per Lugano classification for participants with SLL.
| percentage of participants | Zanubrutinib | Ibrutinib |
|---|---|---|
| Rate of Partial Response With Lymphocytosis (PR-L) or Higher Assessed by the Independent Review Committee | 91.7 (88.2 to 94.5) | 83.1 (78.5 to 87.0) |
The rate of partial response with lymphocytosis or better is defined as the percentage of participants who achieved a complete response or complete response with incomplete bone marrow recovery (CR/CRi), nodular partial response, partial response, or partial response with lymphocytosis as assessed by the investigator. Disease response was assessed according to the iwCLL 2008 criteria, with modification for treatment-related lymphocytosis for participants with CLL and in accordance with Lugano classification for participants with SLL. Partial response with lymphocytosis: blood lymphocytes decreased \< 50% or increased from baseline, and otherwise meeting criteria for PR.
| percentage of participants | Zanubrutinib | Ibrutinib |
|---|---|---|
| Rate of Partial Response With Lymphocytosis (PR-L) or Higher Assessed by the Investigator | 89.9 (86.1 to 93.0) | 82.5 (77.9 to 86.4) |
Overall survival is defined as the time from randomization to the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method.
| months | Zanubrutinib | Ibrutinib |
|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) |
The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. Higher scores in GHS and functional scales indicate better quality of life.
| score on a scale | Zanubrutinib | Ibrutinib |
|---|---|---|
| GHS/QoL Scale at Week 24 | 8.18 (6.25 to 10.12) | 5.18 (3.20 to 7.17) |
| GHS/QoL Scale at Week 48 | 7.28 (5.41 to 9.15) | 5.93 (3.97 to 7.89) |
| Physical Functioning Scale at Week 24 | 6.55 (4.96 to 8.15) | 4.73 (3.08 to 6.38) |
| Physical Functioning Scale at Week 48 | 5.46 (3.87 to 7.04) | 4.31 (2.65 to 5.97) |
| Role Functioning Scale at Week 24 | 6.95 (4.85 to 9.06) | 6.32 (4.14 to 8.50) |
| Role Functioning Scale at Week 48 | 6.81 (4.61 to 9.02) | 5.01 (2.69 to 7.33) |
The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. Lower scores in symptom scales indicate better quality of life.
| score on a scale | Zanubrutinib | Ibrutinib |
|---|---|---|
| Fatigue Symptom Scale at Week 24 | -12.54 (-14.47 to -10.60) | -10.63 (-12.63 to -8.62) |
| Fatigue Symptom Scale at Week 48 | -11.13 (-13.19 to -9.08) | -10.78 (-12.93 to -8.63) |
| Nausea and Vomiting Symptom Scale at Week 24 | -1.21 (-2.03 to -0.38) | -0.92 (-1.77 to -0.07) |
| Nausea and Vomiting Symptom Scale at Week 48 | -0.92 (-1.94 to 0.10) | -0.40 (-1.47 to 0.66) |
| Pain Symptom Scale at Week 24 | -5.06 (-7.21 to -2.91) | -3.63 (-5.85 to -1.42) |
| Pain Symptom Scale at Week 48 | -5.18 (-7.38 to -2.97) | -2.75 (-5.06 to -0.44) |
| Diarrhoea Symptom Scale at Week 24 | -2.11 (-3.80 to -0.42) | -0.52 (-2.27 to 1.22) |
| Diarrhoea Symptom Scale at Week 48 | -3.23 (-4.79 to -1.66) | -1.38 (-3.03 to 0.27) |
The EQ-5D-5L VAS measures a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' A higher score indicates better health outcomes.
| score on a scale | Zanubrutinib | Ibrutinib |
|---|---|---|
| Week 24 | 7.92 ± 18.245 | 3.44 ± 16.972 |
| Week 48 | 7.75 ± 18.806 | 3.92 ± 16.778 |
An adverse event is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to study drug or not. A serious adverse event (SAE) is any untoward medical occurrence that, at any dose: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization * Resulted in disability/incapacity * Resulted in a congenital anomaly/birth defect * Was considered a significant medical AE by the investigator based on medical judgment
| Participants | Zanubrutinib | Ibrutinib |
|---|---|---|
| Any TEAE | 322 | 323 |
| Serious adverse events | 172 | 196 |
Collected over All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Zanubrutinib | 69/327 (21.1%) | 172/324 (53.1%) | 310/324 (95.7%) |
| Ibrutinib | 83/325 (25.5%) | 196/324 (60.5%) | 314/324 (96.9%) |
| Event | Zanubrutinib | Ibrutinib |
|---|---|---|
| COVID-19 pneumoniaInfections and infestations | 33/324 | 22/324 |
| PneumoniaInfections and infestations | 24/324 | 33/324 |
| COVID-19Infections and infestations | 28/324 | 20/324 |
| Atrial fibrillationCardiac disorders | 2/324 | 11/324 |
| Urinary tract infectionInfections and infestations | 7/324 | 10/324 |
| AnaemiaBlood and lymphatic system disorders | 5/324 | 4/324 |
| PyrexiaGeneral disorders | 2/324 | 5/324 |
| DeathGeneral disorders | 4/324 | 3/324 |
| SepsisInfections and infestations | 4/324 | 3/324 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 4/324 | 1/324 |
| Event | Zanubrutinib | Ibrutinib |
|---|---|---|
| COVID-19Infections and infestations | 121/324 | 84/324 |
| Upper respiratory tract infectionInfections and infestations | 95/324 | 64/324 |
| DiarrhoeaGastrointestinal disorders | 61/324 | 83/324 |
| HypertensionVascular disorders | 82/324 | 74/324 |
| NeutropeniaBlood and lymphatic system disorders | 81/324 | 73/324 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 54/324 | 63/324 |
| AnaemiaBlood and lymphatic system disorders | 53/324 | 56/324 |
| FatigueGeneral disorders | 36/324 | 49/324 |
| ContusionInjury, poisoning and procedural complications | 49/324 | 38/324 |
| CoughRespiratory, thoracic and mediastinal disorders | 46/324 | 43/324 |
Intent-to-Treat (ITT) Analysis Set includes all randomized participants
| Age, Categorical(Participants) | Zanubrutinib | Ibrutinib | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 126 | 125 | 251 |
| >=65 years | 201 | 200 | 401 |
| Age, Continuous(years) | Zanubrutinib | Ibrutinib | Total |
|---|---|---|---|
| Median | 67.0 (35 to 90) | 68.0 (35 to 89) | 67.0 (35 to 90) |
| Sex: Female, Male(Participants) | Zanubrutinib | Ibrutinib | Total |
|---|---|---|---|
| Female | 114 | 93 | 207 |
| Male | 213 | 232 | 445 |
| Ethnicity (NIH/OMB)(Participants) | Zanubrutinib | Ibrutinib | Total |
|---|---|---|---|
| Hispanic or Latino | 7 | 13 | 20 |
| Not Hispanic or Latino | 309 | 298 | 607 |
| Unknown or Not Reported | 11 | 14 | 25 |
| Race/Ethnicity, Customized(Participants) | Zanubrutinib | Ibrutinib | Total |
|---|---|---|---|
| Asian | 47 | 44 | 91 |
| Black or African American | 4 | 2 | 6 |
| Native Hawaiian or Pacific Islander | 3 | 0 | 3 |
| White | 261 | 265 | 526 |
| Other | 2 | 2 | 4 |
| Multiple | 1 | 0 | 1 |
| Unknown/Not Reported | 9 | 12 | 21 |
| Geographic Region(Participants) | Zanubrutinib | Ibrutinib | Total |
|---|---|---|---|
| Asia | 49 | 45 | 94 |
| Australia/New Zealand | 28 | 30 | 58 |
| Europe | 198 | 191 | 389 |
| North America | 52 | 59 | 111 |
| Chromosome 17p Deletion (del[17p]) and TP53 Mutation Status(Participants) | Zanubrutinib | Ibrutinib | Total |
|---|---|---|---|
| Del(17p) and/or TP53 mutation | 75 | 75 | 150 |
| Neither Del(17p) nor TP53 mutation | 251 | 250 | 501 |
| Missing | 1 | 0 | 1 |
Showing the first 100 of 115 sites across 15 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See plan description
Access criteria: See plan description
Data sharing details ↗ · beigene.com
Ran from Nov 2018 to primary completion in Aug 2022, 45 months.
Results were first posted in Jul 2023, 11 months after primary completion.
Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 45 months is below that.
Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zanubrutinib
Leukemia, Lymphocytic, Chronic, B-Cell →